JP Morgan Maintains Underweight on BioNTech, Lowers Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Underweight rating on BioNTech (NASDAQ:BNTX) and lowers the price target from $94 to $91.
August 15, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Underweight rating on BioNTech and lowers the price target from $94 to $91.
The lowered price target and maintained Underweight rating by JP Morgan suggest a bearish outlook on BioNTech's stock, likely leading to a short-term negative impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100